Circulating MMP-12 as Potential Biomarker in Evaluating Disease Severity and Efficacy of Sublingual Immunotherapy in Allergic Rhinitis

<div>ROC curve analysis of MMP-12 and MRGPRX2 as promising biomarkers for predicting the efficacy 3 years post-SLIT in AR patients. ROC: receiver operating characteristic; MMP-12: matrix metalloproteinase-12; MRGPRX2: mas-related G protein-coupled receptor-X2; SLIT: sublingual immunotherapy; AR: allergic rhinitis.</div>

Mediators of Inflammation

fig6

Figure 6

Figure 6: Circulating MMP-12 as Potential Biomarker in Evaluating Disease Severity and Efficacy of Sublingual Immunotherapy in Allergic Rhinitis 